Regeneron's Eylea franchise suffers double whammy with sales decline and surprise FDA rejection
After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Aside from a sales slump fueled by a broader downturn in the VEGF medicine market, a crucial prefilled syringe version of the drug's high-dose format was rejected by the FDA last week, Regeneron said in an earnings release.
After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Aside from a sales slump fueled by a broader downturn in the VEGF medicine market, a crucial prefilled syringe version of the drug's high-dose format was rejected by the FDA last week, Regeneron said in an earnings release.
